Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a report issued on Monday, March 10th. Brookline Capital Management analyst K. Dolliver expects that the company will post earnings per share of ($0.88) for the year. Brookline Capital Management has a "Strong-Buy" rating on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Perspective Therapeutics' Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.41) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.59) EPS and FY2026 earnings at ($2.04) EPS.
A number of other equities analysts also recently issued reports on CATX. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. Royal Bank of Canada restated an "outperform" rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Oppenheimer dropped their price target on Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research note on Friday, November 22nd. Scotiabank started coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target on the stock. Finally, Cantor Fitzgerald upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $15.13.
Check Out Our Latest Stock Report on Perspective Therapeutics
Perspective Therapeutics Stock Performance
CATX stock opened at $2.50 on Wednesday. Perspective Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.05. The stock's fifty day moving average price is $3.18 and its 200-day moving average price is $7.48.
Hedge Funds Weigh In On Perspective Therapeutics
Institutional investors have recently bought and sold shares of the stock. US Bancorp DE raised its holdings in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company's stock valued at $88,000 after acquiring an additional 3,866 shares during the period. Los Angeles Capital Management LLC bought a new stake in Perspective Therapeutics during the third quarter valued at about $153,000. WealthPlan Investment Management LLC bought a new stake in Perspective Therapeutics during the third quarter valued at about $4,530,000. Victory Capital Management Inc. raised its holdings in Perspective Therapeutics by 328.7% during the third quarter. Victory Capital Management Inc. now owns 50,460 shares of the company's stock valued at $674,000 after acquiring an additional 38,690 shares during the period. Finally, CIBC Asset Management Inc bought a new stake in Perspective Therapeutics during the third quarter valued at about $259,000. 54.66% of the stock is owned by institutional investors.
Perspective Therapeutics Company Profile
(
Get Free Report)
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Perspective Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.
While Perspective Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
